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ABSTRACT Pneumococcal pili have been shown to influence pneumococcal colonization, disease development, and the inflam-
matory response in mice. The role of the pilus-associated RrgA adhesin in pneumococcal interactions with murine and human
macrophages was investigated. Expression of pili with RrgA enhanced the uptake of pneumococci by murine and humanmacro-
phages that was abolished by antibodies to complement receptor 3 (CR3) and not seen in CR3-deficient macrophages. Recombi-
nant RrgA, but not pilus subunit RrgC, promoted CR3-mediated phagocytosis of coated beads by murine and humanmacro-
phages. Flow cytometry showed that purified CR3 binds pneumococcal cells expressing RrgA, and purified RrgA was shown to
interact with CR3 and its I domain. In vivo, RrgA facilitated spread of pneumococci from the upper airways and peritoneal cav-
ity to the bloodstream. Earlier onset of septicemia andmore rapidly progressing disease was observed in wild-type mice com-
pared to CR3-deficient mice challenged intranasally or intraperitoneally with pneumococci. Motility assays and time-lapse video
microscopy showed that pneumococcal stimulation of macrophage motility required RrgA and CR3. These findings, together
with the observed RrgA-dependent increase of intracellular survivors up to 10 h following macrophage infection, suggest that
RrgA-CR3-mediated phagocytosis promotes systemic pneumococcal spread from local sites.
IMPORTANCE Streptococcus pneumoniae is a major contributor to morbidity and mortality in infectious diseases globally. Symp-
tomatology is mainly due to pneumococcal interactions with host cells leading to an inflammatory response. However, we still
need more knowledge on how pneumococci talk to immune cells and the importance of this interaction. Recently, a novel struc-
ture was identified on the pneumococcal surface, an adhesive pilus found in about 30% of clinical pneumococcal isolates. The
pilus has been suggested to be important for successful spread of antibiotic-resistant pneumococcal clones globally. Here we
sought to identify mechanisms for how the pneumococcal pilin subunit RrgA contributes to disease development by interacting
with host immune cells. Our data suggest a new way for how pneumococci may cross talk with phagocytic cells and affect disease
progression. An increased understanding of these processes may lead to better strategies for how to treat these common infec-
tions.
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Streptococcus pneumoniae, commonly referred to as pneumo-coccus, is a major human pathogen contributing greatly to
morbidity andmortality worldwide, especially in children and the
elderly. Pneumococcal infections cause approximately as many
deaths as tuberculosis and include diseases ranging from milder
respiratory tract infections to more severe diseases such as pneu-
monia, meningitis, and septicemia. Although colonization of the
nasopharynx precedes disease, pneumococci are frequently found
colonizing the nasopharynges of healthy preschool children. The
underlying mechanisms explaining how pneumococci, from a lo-
cal site, pass mucosal barriers to cause systemic disease remains to
be further elucidated.
S. pneumoniae strain T4 (TIGR4) expresses a pilus-like struc-
ture, encoded by the rlrA pilus islet 1, and shown to contribute to
virulence in animal models (1). The rlrA pilus islet 1 is present in
approximately 30%of all pneumococcal isolates (2, 3), depending
on the clonal type, and consists of genes encoding three different
pilus subunit proteins, RrgA, RrgB, and RrgC, which are cova-
lently linked by three pilus-specific sortases. RrgB is the major
stalk protein of the pilus, and in the absence of a pilus shaft, mo-
nomeric RrgA is located on the surface and is sortase-linked to the
cell wall. However, clinical isolates producing RrgA in the absence
of pili have not yet been reported. The pneumococcal pilus and
specifically the RrgA protein promote adhesion to lung epithelial
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cells in vitro and virulence in vivo in murine models (1, 4). The
crystal structure of RrgA was recently solved (5). It was demon-
strated that the 893-residue-long adhesin formed an elongated
structure composed of four domains of which the major domain,
the D3 domain, adopts an integrin I collagen recognition domain
suggested to interact with extracellular matrix (ECM) proteins.
Indeed, purified RrgA has been shown to bind fibronectin,
laminin, and collagen I, but not to vitronectin (6).
The innate immune system involves effectors and immune
cells and constitutes the first line of defense against invading
pathogens. In the lungs, phagocytosis mediated by resident mac-
rophages plays a central role in clearance of pneumococci early in
infection, and bacterium-induced Toll-like receptor 9 (TLR9)-
NF-B signaling has been suggested to enhance the phagocytic
capacity of alveolar macrophages (AMs) (7, 8). It has also been
reported that influenza virus sensitization to pneumococcal infec-
tion might operate via an interferon-induced inhibition of bacte-
rial clearance, mediated by AMs in the lungs (9).
Numerous surface receptors and associated signal transduc-
tion pathways are involved in the phagocytic machinery, leading
to bacterial killing and later to the induction of an adaptive im-
mune response. The complement system acts as a part of the in-
nate immune response by opsonizing microbes in a specific man-
ner. Complement receptors (CRs) on the surfaces of phagocytes
recognize and internalize the opsonized pathogens. Opsonization
of bacteria by immunoglobulins leads to similar enhanced uptake
of pathogens by Fc receptors. Also, opsonin-independent
phagocytosis, where ligands on the surfaces of the microorgan-
isms are directly recognized by receptors on the plasma mem-
branes of phagocytes, has been reported. Scavenger receptors, like
macrophage receptor with a collagenous structure (MARCO),
promote phagocytosis of bacteria nonopsonically and have been
shown to protect against pneumococcal infections (10–12). There
are also receptors that can be involved in either pathway, such as
complement receptor 3 (CR3, CD11b/CD18, Mac-1) (13). CR3 is
expressed on polymorphonuclear leukocytes, monocytes/macro-
phages, and activated lymphocytes and mediates both opsonin-
dependent and -independent phagocytosis. It recognizes multiple
microbial adhesins by direct protein-protein interactions (14, 15).
CR3 binds to a variety of molecules in the host, such as intercel-
lular adhesion molecule 1 (ICAM-1) (16), fibrinogen (17), and
heparin (18). Binding of CR3 induces different functions such as
leukocyte extravasation and migration. Activation of CR3 also
upregulates other key adhesion and defense receptors on leuko-
cytes (19, 20).
Here, we sought to determine whether an interaction can be
found between pneumococcal pili and phagocytes, whether the
pilus-associated adhesin RrgA is required for this process, and if
such an interaction translates into in vivo effects using mouse in-
fection models.
RESULTS
RrgA on pneumococcal pilus 1 promotes nonopsonic comple-
ment receptor 3 (CR3)-dependent uptake of S. pneumoniae by
murine and human macrophages. To examine whether expres-
sion of RrgA affects phagocytosis, pneumococcal strain T4
(TIGR4) expressing RrgA containing pili and mutant derivatives
of T4 were incubated on monolayers of murine bone marrow-
derived macrophages (BMDMs). T4 is an encapsulated and pili-
ated serotype 4 pneumococcal strain originally isolated from a
patient with invasive disease. Its isogenic mutant, the T4rrgA
strain, lacks RrgA but expresses a RrgB- and RrgC-positive pilus
(4). We also created a complemented mutant of T4rrgA,
T4rrgA(lacE::rrgA) in which rrgAwas reinserted into the pneu-
mococcal chromosome in trans.
After 1 h of phagocytosis, the strains expressing pilus-
associated RrgA [T4 and T4rrgA(lacE::rrgA) strains] were in-
ternalized to a significantly higher degree than the rrgA deficient
mutant, the T4rrgA strain (Fig. 1A) (P 0.0005). For a control,
we used cytochalasin D to block actin cytoskeleton rearrangement
in cells. With cytochalasin D treatment, the uptake of pneumo-
cocci was almost completely abolished, and there was no differ-
ence in adherence of the three pneumococcal strains to the cells
(data not shown).
To identify a putative receptor on BMDMs, we considered
CR3, also named integrin CD11b/CD18 or Mac-1. Pretreatment
of BMDMs with anti-CD11b antibodies decreased the uptake of
pneumococcal strain T4 and the T4rrgA(lacE::rrgA) strain to
the level of uptake of the T4rrgA mutant (P 0.001) (Fig. 1A).
Antibody treatment had no effect on the uptake of the T4rrgA
mutant. We also treated murine BMDMs with anti-CD11c anti-
bodies and found that they did not influence uptake of T4, thereby
confirming the antibody specificity in inhibition (Fig. 1A).
To further confirm a role for CR3 in pneumococcal phagocy-
tosis, we performed phagocytosis assays with BMDMs from
CD11b/mice, which lack functional CR3. These macrophages
showed a 40% reduction in the uptake of strain T4 expressing pili
with RrgA (Fig. 1B) (P 0.0012), which is similar to the level of
uptake of the RrgA-deficient bacteria by wild-type macrophages.
When comparing uptake of the different pneumococcal strains in
CD11b/ macrophages, no statistically significant differences
were observed (Fig. 1B). Targeting CD11b by antibodies or its
complete absence only partially inhibited BMDM phagocytosis,
testifying to the role of other phagocytic receptors in pneumococ-
cal uptake by macrophages.
Next we used human macrophages (THP-1 cells) in phagocy-
tosis assays of the T4, T4rrgA, and T4rrgA(lacE::rrgA) strains
(Fig. 1C). A moderate but significant decrease of T4rrgA phago-
cytosis compared to the wild type and the RrgA-complemented
mutant was found. A monoclonal antibody specific for human
CD11b decreased THP-1 phagocytosis only for strain T4 express-
ing wild-type pili but had no effect on the uptake of the T4rrgA
mutant (Fig. 1C).
Recombinant RrgA, but not RrgC, promotes CR3-mediated
phagocytosis of coated beads by murine and human macro-
phages. To directly demonstrate a role for the RrgA adhesin in
phagocytosis, we conjugated full-length recombinant RrgA
(rRrgA) to fluorescent microspheres and monitored uptake by
murine BMDMs and by human THP-1 cells (Fig. 2A). For a rele-
vant control, we made use of rRrgC, an ancillary pilus 1 compo-
nent believed to anchor the completed pilus to the peptidoglycan
cell wall. In both BMDMs andTHP-1 cells, phagocytosis was three
and four times higher for beads coated with rRrgA than for beads
coatedwith rRrgC and bovine serum albumin (BSA), respectively.
Antibodies specific to murine and human CD11b completely in-
hibited phagocytosis of rRrgA-coated beads by murine BMDMs
and human THP-1 cells, respectively (Fig. 2B).
PurifiedCR3bindsdirectly topneumococcal cells expressing
pilus-associated RrgA and to recombinant RrgA. The RrgA ad-
hesin has been demonstrated to bind to a number of extracellular
Orrskog et al.
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matrix proteins, including collagen I, fibronectin, and laminin in
contrast to the other two pilus 1 constituents, RrgB and RrgC (6).
To find evidence for a direct interaction between RrgA-expressing
pneumococci and CR3, we performed flow cytometry analyses of
purified human CR3 (CD11b/CD18) binding to S. pneumoniae
T4, T4rrgA, and T4rrgA(lacE::rrgA) strains, making use of
FIG 1 The pneumococcal pilus subunit RrgA enhances uptake by murine and human macrophages through interaction with CD11b (CR3). (A and B) The
bacteria were labeled with FITC and incubated with monolayers of bone marrow-derived macrophages (BMDMs) for 1 h at an MOI of ca. 60 bacteria per cell,
and the fluorescence intensity wasmeasured by FACS. The phagocytic index for each sample was calculated bymultiplying the percentage of internalized cells by
the mean fluorescence intensity and dividing this by the mean of the wild-type (T4) sample multiplied with the percentage of FITC-positive cells. (A)
Phagocytosis assays were performed with murine BMDMs. The mutant lacking RrgA (T4rrgA) was taken up to a significantly lower extent than the bacteria
expressing RrgA (T4 and T4rrgAlacE::rrgA strains). BMDMs were pretreated with antibodies (Ab) against mouse CD11b. This inhibited the uptake of the T4
and T4rrgA(lacE::rrgA) strains, which under these conditions reached levels similar to those of the uptake of the T4rrgAmutant. The antibody treatment did
not, however, affect the uptake of the T4rrgAmutant. Antibodies directed against mouse CD11c did not influence the uptake of T4. Each condition was done
in triplicate and was repeated at least three times. Values that were significantly different (P 0.001) are indicated by a bar and three asterisks. Values that were
not significantly different are indicated by a bar and n.s. (for not significant). (B) CR3-deficient (CD11b/) BMDMs exhibited lower levels of uptake of T4 than
macrophages from wild-type mice (Wt). The decrease was comparable to the levels of uptake of the T4rrgAmutant by wild-type macrophages. There were no
statistically significant differences in the levels of uptake of the different pneumococcal strains by the CR3-deficient macrophages. Each experiment was done in
triplicate and was repeated at least three times. Values that were significantly different (P 0.01) are indicated by a bar and two asterisks. Values that were not
significantly different are indicated by a bar and n.s. (for not significant). (C) In concordance with the findings in murine macrophages, a mutant lacking RrgA
(T4rrgA) was taken up by human phorbol myristate acetate (PMA)-differentiated THP-1 cells to a significantly lower extent than bacteria expressing RrgA.
Furthermore, a specific antibody against human CD11b inhibited the uptake of the T4 strain but did not significantly affect the uptake of the T4rrgAmutant.
Values aremeans plus standard errors of themeans (SEM) (error bars). Values that were significantly different (P 0.05) are indicated by a bar and one asterisk.
Values that were not significantly different are indicated by a bar and n.s. (for not significant).
RrgA-CR3 Interactions Affect Pneumococcal Disease
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anti-CD11b monoclonal antibody (MAb) (peridinin chlorophyll
protein [PerCp]-Cy5.5 labeled). CR3 bound efficiently to the two
RrgA-expressing strains, whereas there was no binding to the
T4rrgA strain (Fig. 3A). The addition of extracellularmatrix pro-
teins (collagen I, fibronectin, laminin, or vitronectin) did not in-
hibit or enhance CR3 binding to pneumococcal cells expressing
RrgA (see Fig. S1 in the supplemental material), suggesting a di-
rect interaction between CR3 and RrgA.
Next we studied the interaction between purified CR3 and
rRrgA using a far-Western dot blotting technique in which puri-
fied human CR3 was blotted onto nitrocellulose membranes in
concentrations of 0.5, 1, 5, and 10g (Fig. 3B). Sincemost known
interactions between CR3 and its ligands occur via the CD11b
integrin domain, purified CD11b-I was also used at equivalent
concentrations. Five micrograms of BSA was used as a negative
control. For a probe, we used 2 g of full-length recombinant
RrgA and monitored binding with a specific rabbit antibody
against RrgA (anti-RrgA). rRrgA was found to bind in a dose-
dependent manner to both CR3 and CD11b-I (Fig. 3B). Further-
more, binding to purified CR3 and CD11b-1 decreased when a
specific antibody against CD18 and CD11b was used in an ELISA
(Fig. 3C and D). Also, rRrgA binding to CR3 and CD11b-I was
dependent on the concentration of the
RrgA adhesin (see Fig. S2A and S2B in the
supplemental material).
Absence of RrgA and/or murine ex-
pression of CR3 decreased the number
of bacteria in the bloodstream early af-
ter intranasal and intraperitoneal chal-
lenge. We next investigated whether
pneumococcal expression of RrgA and
host expression of CR3 affects virulence
and dissemination of pneumococci from
a local site to the bloodstream. As intra-
nasal (i.n.) inoculation of pneumococci
inmicemimics the natural route of infec-
tion in humans, we first investigated
whether RrgA and CR3 influence disease
kinetics in an infection model of pneu-
mococcal pneumonia. We inoculated 5
 106 CFU i.n. into C57BL/6 mice and
monitored the animals up to 72 h postin-
fection (Fig. 4A to C).Wild-typemice in-
fected with the T4 or T4rrgA(lacE::
rrgA) strain showed increased mortality
compared to wild-type mice infected
with the T4rrgA strain (Fig. 4A) (P 
0.0187 in the survival analysis with the
Kaplan-Meier log rank test). Further-
more, the two strains expressing RrgA
could be detected in blood samples from
wild-type mice as early as 12 h postinfec-
tion, whereas no T4rrgA bacteria were
recovered from blood samples from any
mice at this early time point (Fig. 4B).
CD11b/ mice inoculated i.n. with the
T4 strain succumbed later to infection
than wild-type mice challenged with the
same strain (Fig. 4A), and CR3-deficient
mice also exhibited a delay in the onset of
bacteremia (Fig. 4B and C).
When we challenged C57BL/6 mice intraperitoneally (i.p.)
with the T4 strain and the different isogenicmutants, we observed
that mice infected with the T4rrgA mutant lacking RrgA sur-
vived significantly longer than mice infected with either the T4 or
T4rrgA(lacE::rrgA) strain both expressing RrgA (Fig. 5A) (P
0.0025 in the survival analysis with the Kaplan-Meier log rank
test) (4). The prolonged survival of mice infected i.p. with the
T4rrgA mutant was accompanied by lower levels of bacteria in
the bloodstream (Fig. 5B).
To rule out the possibility that the prolonged survival of mice
infected with the T4rrgA mutant either i.n. or i.p. was due to
slower growth of the bacteria in blood, we infected mice intrave-
nously (i.v.) with the T4 strain and the T4rrgAmutant. Using the
i.v. infection route, therewere no differences in the survival rate or
bacterial growth in blood samples frommice infectedwith the two
strains (Fig. 5C and D).
Finally, we investigated whether a lack of CR3 expression af-
fected the survival of mice after i.p. inoculation with the T4 or
T4rrgA strain. When we performed i.p. experiments, we ob-
served that there was a delay in the onset of symptoms and a
significantly longer overall survival time of CR3-deficient
FIG 2 rRrgA promotes uptake of latex beads into macrophages. (A) BMDMs and THP-1 cells were
challenged with latex beads covered with rRrgA (beads-rRrgA) or with rRrgC (beads-rRrgC) or with
bovine serum albumin (BSA) (beads-BSA). We compared the number of coated beads that were taken
up by both murine and human macrophages using BMDMs from mice as well as human PMA-
differentiated THP-1 cells. The number of phagocytosed beads increased significantly when the beads
were coated with rRrgA. (B) Pretreatment with mouse or human CD11b-specific antibodies signifi-
cantly blocked the CD11b-dependent uptake of beads coated with rRrgA (beads-rRrgA CD11b Ab)
without influencing the number of internalized uncoated beads (beads CD11b Ab) in BMDMs and
THP-1 cells, respectively. Each treatmentwas done in duplicate four times. For each sample, the number
of internalized beadswas counted in aminimumof 10 visual fields containing at least 10 cells. Values are
means plus SEM (error bars). Values that are significantly different by the Mann-Whitney U test are
indicated by bars and asterisks as follows: **, P 0.01; ***, P 0.0002; ****, P 0.0001.
Orrskog et al.
4 ® mbio.asm.org January/February 2013 Volume 4 Issue 1 e00535-12
 
m
bio.asm
.org
 o
n
 Septem
ber 21, 2016 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
(CD11b/) mice compared to wild-typemice (P 0.0051 in the
survival analysis with the Kaplan-Meier log rank test) (Fig. 5E).
CD11b/ mice had lower numbers of CFUs in blood when in-
fected with both T4 and T4rrgA strains
compared to wild-type mice infected
with T4, arguing that the dissemination
of RrgA-expressing pneumococci is im-
paired in CD11b/mice (Fig. 5F).
Bacterial expression of the pilus-
associated RrgA adhesin results in
higher numbers of intracellular survi-
vors at late time points after phagocyto-
sis. The results presented so far suggest
that the RrgA adhesin, an ancillary pro-
tein of the pneumococcal 1 pilus, en-
hances phagocytosis through a direct in-
teraction with the CR3 receptor
expressed on murine and human macro-
phages. We expected that enhanced
phagocytosis in vitrowould translate into
decreased virulence in vivo. In contrast,
expression of RrgA in the bacteria to-
gether with CR3 in the host promoted
bacterial virulence in mice and an early
appearance of bacteria in the blood-
stream after local infection.
To begin explaining these results, we
first monitored the fate of RrgA-
expressing and non-RrgA-expressing
pneumococci after phagocytosis. The up-
take of bacteria by macrophages leads to
formation of phagosomes, where bacteria
confront intracellular killing mecha-
nisms. We monitored intracellular sur-
vival by performing gentamicin protec-
tion assays where T4, T4rrgA, and
T4rrgA(lacE::rrgA) strains were incu-
bated with macrophages (BMDMs). Af-
ter antibiotic killing of extracellular bac-
teria, the number of internalized viable
pneumococci was determined by quanti-
tative plating at various time points.
There were significantly fewer CFUs of
the T4rrgA mutant inside the macro-
phages at the beginning of the experiment
(Fig. 6) (P 0.0011), which further sup-
ported the differences in uptake observed
in the fluorescence-activated cell sorting
(FACS)-based phagocytosis assay
(Fig. 1). The rate of bacterial killing was
similar for all pneumococcal strains
(Fig. 6). Interestingly, the increased up-
take of RrgA-expressing bacteria and the
unaffected intracellular killing rate re-
sulted in significantly higher numbers of
survivors for the T4 and T4rrgA(lacE::
rrgA) strains compared to the T4rrgA
strain even 10 h after infection (P 0.05).
The interaction between RrgA and
CR3 leads to increased motility and mi-
gratory behavior of murine BMDMs and human THP-1 cells.
CR3 is a highly versatile pattern recognition receptor that when
ligated activates leukocytes via signaling complexes and actin re-
FIG 3 Pneumococcal cell surface-associated and purified RrgA binds to purified human CR3 as well as
to theCD11b-I domain. (A) Flow cytometry analysis of CR3binding toRrgAprotein associatedwith the
S. pneumoniae cell surface. T4 strain and its mutants (108 live bacteria) were incubated with 10g/ml of
purified CR3 (histograms outlined by thick black lines) or PBS (light gray filled histograms), and CR3
binding was detected with an anti-CD11b MAb (PerCp-Cy5.5 labeled) at a final concentration of
10g/ml. CR3 binding is observed by a shift to the right in the population of bacteria incubatedwith the
purified CR3 protein and expressing RrgA on their surface, i.e., T4 and T4rrgA(lacE::rrgA) cells,
compared with cells incubated with PBS (control) (gray) or with CR3 but not expressing RrgA, i.e.,
T4rrgA cells. Binding was calculated by subtracting the mean fluorescence intensity of bacteria incu-
bated with purified CR3 protein from that of the bacteria incubated with PBS (MFI). The average
MFI values from three independent experiments are shown as numbers in the boxes in the top
right-hand corner. (B) Human CR3 or CD11b I domain-GST was blotted in different concentrations
onto a nitrocellulose filter, blocked, and subsequently incubated with 2 g of rRrgA. Dose-dependent
binding was detected using an antibody directed against RrgA. BSA or GST was used as a negative
control. (C and D) rRrgA binding to purified CR3 (C) and to CD11b-I domain (dom) (D) was signif-
icantly decreased when specific antibody against CD18 (7E4 Mab) and CD11b (MEM170 Mab) were
used, respectively, to inhibit the binding in an ELISA. Values are means plus standard deviations (SD)
(error bars). Values that are significantly different (P 0.0001) are indicated by a bar and three asterisks.
OD492 nm, optical density at 492 nm.
RrgA-CR3 Interactions Affect Pneumococcal Disease
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organization. This activation not only mediates phagocytosis but
also promotes leukocyte transmigration. The motility/migration
of immune cells affects infection, inflammation, and wound heal-
ing, and pathogens may utilize this cellular function in order to
disseminate within the host (21–24). Therefore, we investigated
whether the identified interaction between RrgA andCR3 affected
the motility/migration of murine BMDMs (Fig. 7A) and human
THP-1 cells (Fig. 7B). Motility/migration assays were performed
using a Transwell system, in which we determined that strain T4
expressing RrgA increased the motility of BMDMs and THP-1
cells approximately twofold compared to untreated control cells
(Fig. 7A, P  0.01, and Fig. 7B, P  0.05). Interestingly, the
T4rrgA strain, lacking RrgA, did not induce the motility/migra-
tion of macrophages, while induction of motility/migration was
restored in the complemented strain, T4rrgA(lacE::rrgA)
strain. BothCR3-expressing andCR3-deficient (CD11b/)mac-
rophages migrated across the Transwell chamber when macro-
phage chemoattractant 1 (MCP-1) was present in the bottom
chamber. However, the two RrgA-expressing strains failed to in-
duce motility/migration in CR3-deficient (CD11b/) BMDMs
(Fig. 7A), supporting the role for this receptor in macrophage
motility/migration upon interaction with pneumococcal RrgA.
Finally, when BMDMs were preincubated with antibodies against
CD11b, there were no differences in motility/migration between
untreated control cells and cells challenged with RrgA or RrgA
bacteria (data not shown).
To further confirm that the motile/migratory behavior of BM-
DMs is induced by RrgA and CR3, we performed additional mo-
tility assays using time-lapse video microscopy. Single-cell track-
ing revealed that the motility/migration of BMDMs was induced
FIG 4 RrgA induces faster onset of bacteremia and decreased survival after intranasal challenge of mice. Mice were inoculated i.n. with ca. 5  106 CFU per
mouse. Blood samples were taken at various time points, and survival was assessed. (A) Wild-type mice infected with the T4rrgA mutant and CR3-deficient
(CD11b/) mice survived to a higher extent (80 and 55%, respectively) than wild-type (Wt) mice infected with strains expressing RrgA, i.e., T4 and
T4rrgA(lacE::rrgA) strains, which had survival rates of 45 and 40%, respectively. Survival was analyzed using theKaplan-Meier log rank test. The asterisk refers
to wild-type mice infected with the T4rrgA strain compared to the T4 strain. (B and C) Percentages of bacteremic mice from the start of the experiment.
Wild-type mice inoculated with RrgA bacteria were bacteremic 12 h postinfection. Bacteria appeared later in blood samples from wild-type mice infected
intranasally with the T4rrgAmutant and CR3-deficient (CD11b/) mice infected with the T4 strain. There were 10mice per group in each of the i.n. infection
experiments, and the experimentswere repeated three times. The value forwild-typemice infectedwith theT4rrgAmutantwas significantly different (P 0.05)
from the value for wild-type mice infected with T4 strain as indicated by the asterisk.
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by pneumococci expressing RrgA [T4 and T4rrgA(lacE::rrgA)
strains], but not by the T4rrgA strain (P  0.001 [Fig. 7C and
D]). CR3-deficient BMDMs were not affected by the addition of
any of the pneumococcal strains; their motility/migration re-
mained at control levels (Fig. 7C and D). Also, the velocity of the
cells was measured using this method, which revealed that cells
infected with T4 and T4rrgA(lacE::rrgA) strains moved faster
than uninfected control cells (Fig. 7D) (P 0.00015). In contrast,
BMDMs infected with the T4rrgA mutant did not move faster
than the control cells. The velocity of the CR3-deficient BMDMs
did not increase after bacterial challenge and remained at control
levels throughout the experiment.
DISCUSSION
We show for the first time that expression of pili on the pneumo-
coccal surface leads to enhanced phagocytosis bymurine BMDMs
and humanmacrophages (THP-1 cells). Furthermore, we provide
evidence that the pilus-associated adhesin RrgA, rather than the
pilus-forming RrgB or pilus-associated RrgC subunits, promotes
phagocytosis (25). Moreover, we show that a specific antibody
FIG 5 Pneumococcal expression of RrgA andmouse expression of CR3 promotes dissemination of bacteria from the peritoneal cavity to the bloodstream.Mice
were infected i.p. or i.v. with ca. 5  106 or 5  105 CFU per mouse, respectively. Blood samples were taken at various time points. (A) Wild type (Wt) mice
infected i.p. with the strain lacking RrgA (T4rrgA) survived significantly longer than mice infected with strains expressing RrgA, i.e., T4 and T4rrgA(lacE::
rrgA) strains (P 0.01). (B) The levels of bacteria lacking RrgAwere lower in the bloodstreamofwild-typemice. (C andD)Wild-typemice infected i.v. exhibited
similar survival curves regardless of which strain they were infected with (C), and there were no differences in the growth of the bacteria in the blood of wild-type
mice (D). (E) CR3-deficient (CD11b/) mice infected i.p. with either T4 or T4rrgA survived significantly longer than wild-type mice. (F) T4 and T4rrgA
strains appeared later and in lower numbers in the bloodstream of CR3-deficient mice compared to wild-type mice. There were no statistically significant
differences between the different groups of CR3-deficient mice compared to wild-type mice infected with the T4 strain. There were 10 and 5 mice per group in
each of the i.p. and i.v. infection experiments, respectively, and the experiments were repeated three times. Values that are significantly different are indicated by
asterisks as follows: *, P 0.05; **, P 0.01; ***, P 0.001. n.s., not significant.
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against murine CD11b decreased phagocytosis by BMDMs and
THP-1 cells of pneumococci expressing RrgA to a similar level of
phagocytosis as that of RrgA bacteria, suggesting that RrgA pro-
motes phagocytosis via CR3. Finally, interaction between RrgA
and CR3 appears to be direct andmediated by the CD11b integrin
domain of CR3, thereby representing the first identified cellular
receptor for a Gram-positive pilus. Even though RrgA has been
shown to interact with a number of extracellular matrix proteins,
purified CR3 binding to RrgA-expressing pneumococci was not
affected by the addition of extracellular matrix proteins, like col-
lagen 1, known to interact with either of these two proteins (6).
Our data demonstrate that internalization of RrgA and
RrgA bacteria follows a similar route, leading to phagosome for-
mation and intracellular killing. However, pneumococci express-
ing RrgA were phagocytosed to a greater extent and BMDMs har-
bored higher numbers of viable RrgA thanRrgA bacteria over a
longer time period (at least 10 h). Pneumococci produce several
components toxic to macrophages, such as pneumolysin and
H2O2, and therefore, prolonged intracellular survival time might
lead to death of infected macrophages prior to the complete erad-
ication of ingested bacteria.
When pneumococci expressing RrgA were injected intrana-
sally and intraperitoneally into wild-type mice, they reached the
bloodstream faster and in higher numbers compared to RrgA
bacteria which, irrespective of infection route, also resulted in an
earlier onset of severe disease. In contrast, RrgA-expressing or
non-RrgA-expressing pneumococci did not differ in growth after
i.v. challenge, and the time to onset of severe disease was also not
affected by RrgA. This suggests that RrgA does not promote resis-
tance to clearing mechanisms in the bloodstream.
Expression of RrgA and CR3 was required for rapid appear-
ance of bacteria in the bloodstream when mice were challenged
intranasally or intraperitoneally. This supports a role for an inter-
action between these proteins in vivo for pneumococcal dissemi-
nation.
It has been demonstrated that CR3 is upregulated on AMs in
the lungs after infection with S. pneumoniae (26). AMs are central
to the normal surveillance of pneumococci. They may, however,
have a dual function in host defense, as it was recently demon-
strated that AMs migrate from the lungs to the lung-draining
lymph nodes early after infectionwith an S. pneumoniae 6B isolate
(27). Also, the migration of activated macrophages from the peri-
toneal cavity to the lymph nodes and blood has been shown to
depend onCR3 (28). Thus, activatedmacrophages carrying pneu-
mococci might migrate in a CR3-dependent manner to regional
lymph nodes, and from there, infected phagocytic cells or liber-
ated live bacteria are thought to reach the bloodstream, thereby
contributing to systemic spread from local sites. However, further
in vivo studies are needed to demonstrate that pneumococci can
be translocated into the bloodstream via infected immune cells.
Also, it is important to stress that other pneumococcal virulence
properties, such as PspC, might mediate a direct translocation of
bacteria across biological barriers.
For a commensal pathogen like Streptococcus pneumoniae,
where healthy carriage vastly dominates over disease, each inter-
action between microbe and host may have dual effects, some-
times favoring the host and other times the microbe. Here we
demonstrate that the pilus-associated adhesin RrgA promotes
phagocytosis by BMDMs in a process requiring CR3. This process
is likely to enhance bacterial clearance. However, the simultane-
ous activation ofmotility andmigratory behavior ofmacrophages
may tilt the balance in favor of the ingestedmicrobe. The bistabil-
ity of pilus expression in a pneumococcal population (29, 30) and
the fact that only a subset of pneumococcal strains harbor the pilus
1 islet are additional arguments for the dual role of pneumococcal
pili in its interaction with the host.
MATERIALS AND METHODS
Bacterial strains and construction of mutants. S. pneumoniae T4
(TIGR4) of serotype 4 belongs to a clone (ST205) with high invasive
disease potential in Sweden (31–33). The insertion-deletion mutagenesis
used for creating the rrgA mutant strain T4rrgA, is described elsewhere
(1, 34). Complementation in trans was achieved by inserting a second,
intact copy of rrgA into the lacE lactose utilization operon, creating the
T4rrgA(lacE::rrgA) strain (4, 35). Mutants were checked by PCR, se-
quencing, and immunogenicity using antibodies to pilin subunits.
Murine BMDMs and human macrophage-like THP-1 cells.Murine
BMDMswere extracted (7, 36), and cells were plated in 24-well plates (1
106 cells per well) and incubated for 7 days at 37°C and 5% CO2. Human
monocytic leukemia THP-1 cells (American Type Culture Collection
[ATCC], Manassas, VA) were cultured in RPMI 1640 (Invitrogen) sup-
plemented with 10% heat-inactivated fetal calf serum (FCSi), 2 mM
L-glutamine, and 10 mM HEPES. To induce differentiation, THP-1 cells
(5 105 cells per well) were seeded onto a 24-well plate with 100 ng/ml of
phorbol myristate acetate (PMA) (Sigma) for 30 h at 37°C and 5% CO2.
Before use, cells were washed to remove nonadherent cells. Each condi-
FIG 6 Killing by macrophages is not affected by the presence of RrgA, but
intracellular bacteria are found up to 10 h postchallenge. Bacteria were incu-
bated ontomonolayers of BMDMs for 1 h. Extracellular bacteria were killed by
the addition of gentamicin to the assay medium. At various time points, cells
were lysed with 2% saponin, and viable bacteria were determined by plating
serial dilutions. The rate of bacterial death was similar for all strains, but bac-
teria expressing RrgA, i.e., T4 andT4rrgA(lacE::rrgA) strains, were taken up
to a greater extent, which led to higher numbers of intracellular bacteria after
10 h. Each treatment was done in triplicate and was repeated at least three
times. Values that are significantly different are indicated by asterisks as fol-
lows: *, P 0.05; **, P 0.01.
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FIG 7 The interaction between RrgA and CR3 leads to enhancedmotility of murine and humanmacrophages. Wild-type (Wt) and CR3-deficient (CD11b/)
BMDMs were challenged with pneumococci. (A) Macrophage motility was measured using a Transwell system. The percentages of cells that migrated were
calculated by dividing the output by the input. In wild-type BMDMs, the T4 strain increased the motility of macrophages approximately twofold compared to
the untreated control (CTR), but the T4rrgAmutant failed to do so. The T4rrgA(lacE::rrgA) strain inducedmotility to levels similar to those of the T4 strain.
No statistically significant differencewas foundbetween cells infectedwithT4. All strains failed to inducemotility inCR3-deficientmacrophages, but the addition
(Continued)
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tion was performed in triplicate, and the experiments were repeated at
least three times.
Mouse challenge. The mice were 6 to 10 weeks old and were matched
by age and sex. The mice were inoculated intranasally, intraperitoneally,
or intravenously with ca. 5  106 CFU per mouse. Bacterial growth in
bloodwasmonitored by taking blood samples from the tail at various time
points and plating the samples in serial dilutions on blood agar plates. The
health status of themice was carefully monitored, and clinical scores were
given.
In vitro phagocytosis assays. Bacteria were resuspended in a solution
containing 2.5 mg fluorescein isothiocyanate (FITC) (isomer I; Sigma),
1 ml dimethyl sulfoxide (DMSO) (Sigma), and 9 ml FITC buffer (0.05 M
Na2CO3 [Merck, Darmstadt, Germany] and 0.1 M NaCl [Merck] in
double-distilled water) and incubated on ice for 1 h. After the bacteria
were washed 3 times, macrophages were challenged with FITC-labeled
pneumococci at amultiplicity of infection (MOI) of about 60 bacteria per
cell, spun down at 1,500 rpm for 5 min, and incubated for 60 min at 37°C
and 5% CO2. Serum-free RPMI 1640 (Gibco/Invitrogen) supplemented
with 2 mM glutamine and 10 mM HEPES was used as assay medium.
Following bacterial challenge, the cells were washed 3 times with cold
phosphate-buffered saline (PBS). The cells were detached by 15- to 30-
min incubation on ice with PBS supplemented with 5 mM EDTA at pH
8.0 and 4.0 mg ml1 lidocaine (Sigma). The cells were transferred to
96-well V-bottom plates, washed in PBS, and resuspended in 2% parafor-
maldehyde (Sigma). Before data acquisition by FACS, extracellular fluo-
rescence was quenched by adding trypan blue (Sigma) at pH 5.5. To in-
hibit phagocytosis, 10 g ml1 of cytochalasin D (Sigma) was added
15 min prior to bacterial challenge. For antibody blocking experiments,
the following affinity-purified antibodies were used: anti-mouse CD11c
(N418), anti-mouse CD11b (M1/70) (eBioscience Inc., San Diego, CA)
and anti-human CD11b (VIM12) (Invitrogen). BMDMs were pretreated
with selected anti-mouse antibody and THP-1 cells were pretreated with
selected anti-human antibody at a concentration of 20gl1 for 30min
at 37°C and 5% CO2 prior to bacterial challenge. During FACS acquisi-
tion, 1 104 cells were counted in each sample. Each conditionwas added
in triplicate, and the experiments were repeated at least three times. The
phagocytic index for each sample was calculated by multiplying the per-
centage of FITC-positive cells with themeanfluorescence intensity (MFI),
and dividing this by the mean MFI for the wild-type (T4) samples multi-
plied with the percentage of FITC-positive cells.
For the microbead phagocytosis assays, we used full-length wild-type
rRrgA (amino acid [aa] 39 to aa 862) (1, 4, 37), full-length wild-type
rRrgC (1, 4), and BSA conjugated to carboxylate-modified yellow-green
fluorescent microsphere (fluorosphere carboxylate from Molecular
Probes, Invitrogen) according to themanufacturer’s protocol. THP-1 and
BMDM cells, differentiated onto chamber slides (Nunc, Rochester, NY),
were treated with 10 g ml1 of latex beads alone or beads covered with
rRrgA, rRrgC, or BSA and incubated for 3 h at 37°C and 5% CO2. The
inhibition assay was performed as previously described using anti-mouse
(M1/70) and anti-human (VIM12) anti-CD11b antibodies. Each treat-
ment was repeated in duplicate. Each preparation was examined at100
magnification under oil immersion. At least 10 visual fields for each sam-
ple containing at least 10 or more cells were selected in a random fashion,
and the number of internalized beads was counted manually, taking care
to exclude beads that were only adherent to the cell surface. Differences in
the number of beads were tested with the nonparametric Mann-Whitney
U test.
Purification of CR3 (CD11b/CD18). Human CD11b/CD18 integrin
was purified from human blood buffy coat cell lysates by affinity chroma-
tography on MEM170 monoclonal antibody-Sepharose and eluted at
pH 11.5 in the presence of 2 mMMgCl2 and 1% octyl glucoside. Human
blood buffy coats were from Finnish Red Cross Blood Transfusion Ser-
vice, Helsinki, Finland. Integrin purity was checked by polyacrylamide gel
electrophoresis in the presence of SDS (see Fig. S3 in the supplemental
material).
Flow cytometry analysis of CR3 binding to pneumococci. FACS
analysiswas performed to quantify the binding ofCR3 toRrgA-expressing
pneumococci. Bacteria were grown overnight on solid medium and then
harvested into PBS. Bacteria (108 CFU) were incubated with 10 g/ml of
purified CR3 (CD11b/CD18) or with PBS as a negative control for 30min
at 37°C. After the bacteria were washed twice in PBS containing 0.1%BSA
[PBS-BSA (0.1%)], binding was detected following incubation with an
anti-CD11b MAb labeled with PerCp-Cy5.5 (BD BioScience) at a final
concentration of 10gml1 for 1 h on ice. The cells were washed twice in
PBS-BSA (0.1%) and once in PBS and then fixed in 2%paraformaldehyde
for 20 min at room temperature. Finally, the bacteria were washed, and
the fluorescence intensity was analyzed by a flow cytometer (CyAn ADP;
Beckman Coulter). Bacteria were detected using log forward and log side
scatter dot plots, and a gating region was set to exclude debris and larger
aggregates of bacteria. A total of 1 104 bacteria (events) were analyzed
for fluorescence using log scale amplifications. Comparison between the
fluorescence intensity of the bacteria incubated with purified CR3 with
that of bacteria incubated with PBS alone were illustrated by two-
dimensional overlaid histograms representing fluorescence intensities
calculated with voltage adjustment at FL4 linear channel. FACS results
were also expressed as the change in the mean fluorescence intensity
(MFI), where MFI was calculated by subtracting the mean fluores-
cence intensity of the bacteria incubated with purified CR3 from that of
bacteria incubated with PBS alone.
Far-Western blots. Human CR3 (CD11b/CD18) or CD11b-I
domain-GST was blotted onto nitrocellulose membranes using the Man-
ifold system in concentrations of 0.5, 1, 5, and 10g; 5g of BSA and 5g
of glutathione S-transferase (GST) were used as negative controls. The
membranes were blocked with PBS with 0.01% Tween 20 [PBS-Tween
(0.01%)] and 5%milk for 30 min at room temperature. The membranes
were washed briefly and incubated with 2 g of rRrgA in the presence of
PBS-Tween (0.01%) and 1%milk overnight at 4°C. Themembranes were
washed, primary antibody (Rbanti-RrgA [1:1,000]) was added, and the
membranes were incubated for 3 h at room temperature on a rocking
platform. Finally, the membranes were incubated with secondary anti-
body (anti-Rb peroxidase [1:2,000]; Sigma) for 1 h. Experiments were
repeated three times, and representative experiments are shown.
ELISA. To assess direct binding of CR3 (CD11b/CD18) and CD11b I
domain-GST to the rRrgA protein, microtiter plates were coated over-
night at 4°C with 10 g/ml of purified CR3 (or CD11b I domain-GST).
Subsequent steps were conducted at room temperature (RT) for 1 h each.
Nonspecific binding sites were blocked with PBS-BSA (3%), followed by
the addition of rRrgA (different concentrations from 0 to 200 ng per well)
in PBS-Tween (0.01%) (PBST). Bound rRrgA was detected with a specific
antibody against rRrgA (Rbanti-RrgA) and anti-rabbit serum conju-
gated to horseradish peroxidase (Sigma), both diluted 1:5,000 in PBST.
Sigmafast-OPD (o-phenylenediamine dihydrochloride) (Sigma) was
used for detection, and absorbance wasmeasured at 492 nm. In inhibition
assays, CR3 and CD11b I domain-GST were pretreated with 25 g/ml of
Figure Legend Continued
of macrophage chemoattractant protein 1 (MCP-1) in the bottom chamber led to increased migration of wild-type and CR3-deficient cells. (B) The presence of
RrgA also enhanced the motility of human macrophages (THP-1 cells). (C to E) Motility was monitored using time-lapse video microscopy for up to 6 h. (C)
Representative pictures illustrating all cell movements (red), FITC-labeled pneumococci (green), and BMDMs (gray). (D) Wild-type BMDMs infected with
strains expressing RrgA were more motile than those infected with the T4rrgAmutant. (E) T4 and T4rrgA(lacE::rrgA) strains, but not the T4rrgA strain,
moved faster than untreated controls. (D and E) CR3-deficient macrophages did not display either induction of motility or an increase in velocity when
challengedwith any of the pneumococcal strains. Values that are significantly different are indicated by bars and asterisks as follows: *, P 0.05; **, P 0.01; ***,
P 0.001. Values that were not significantly different are indicated by a bar and n.s. (for not significant).
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anti-CD18 7E4 MAb and anti-CD11b MEM170 MAb, respectively, for
30 min at RT.
In vitro gentamicin protection assay. The gentamicin protection as-
say was performed as described elsewhere (7).
In vitro motility assays. Differentiated BMDM cells were seeded in
serum-free medium (RPMI 1640 supplemented with 2 mM glutamine
and 10 mMHEPES) in small petri dishes (35 by 10 mm) at a density of 1
 106 cells per dish. The cells were either left untreated (control) or chal-
lenged with pneumococci at an MOI of ca. 60 bacteria per cell, or recom-
binant mouse MCP-1 (10 ng ml1; Invitrogen) was added to the bottom
chamber (38). After 1.5 h, gentamicin was added to the medium
(400g ml1). After an additional 1.5 h, the cells were gently scraped off,
counted (input), and transferred to Transwell inserts containing RPMI
1640, and supplemented with 2 mM glutamine, 10 mM HEPES,
100 g ml1 gentamicin, and 10% FCS (time point zero). Additionally,
samples were taken from the medium to ensure that the extracellular
bacteria were killed. The cells were incubated for 15 h before the inserts
were removed, and the cells in the lower wells were scraped off and
counted (output). The percentage of migrated cells was calculated by di-
viding the output by the input. Each conditionwas added in triplicate, and
the experiments were repeated at least three times.
Time-lapse videomicroscopy.Time-lapse videomicroscopywas per-
formed by the method of Behnsen et al. (39).
Statistical analysis. In vitro assays were analyzed using one-way anal-
ysis of variance (ANOVA) with Bonferroni’s posttest (mean fluorescence
intensity, CFU numbers, andmotile cells), unless otherwise stated. In vivo
assayswere analyzed usingKaplan-Meier log rank test (survival), Kruskal-
Wallis test with Dunn’s posttest (CFU numbers), or chi-square test and
Fisher’s exact test (proportion of bacteremic mice). Graph Pad Prism 4.0
software was used (Graph Pad Software, Inc.), and a P value of0.05 was
considered statistically significant.
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